

**Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists**

Reference Number: CP.PMN.183

Effective Date: 09.19.18

Last Review Date: 02.26

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

The following agents contain a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist and require prior authorization: dulaglutide (Trulicity<sup>®</sup>), exenatide ER (Bydureon BCise<sup>®</sup>), exenatide IR (Byetta<sup>®</sup>)<sup>†</sup>, liraglutide (Victoza<sup>®</sup>), liraglutide/insulin degludec (Xultophy<sup>®</sup>), semaglutide (Ozempic<sup>®</sup>, Rybelsus<sup>®</sup>), tirzepatide\* (Mounjaro<sup>™</sup>), insulin glargine/ lixisenatide (Soliqua<sup>®</sup>).

*\*Tirzepatide is a combination GLP-1 and glucose-dependent insulintropic polypeptide (GIP) receptor agonist.*

*†The manufacturer of Bydureon BCise and Byetta, AstraZeneca, is discontinuing these products effective January 1<sup>st</sup>, 2025.*

**FDA Approved Indication(s)**

GLP-1 receptor agonists are indicated as adjunct to diet and exercise to improve glycemic control with type 2 diabetes mellitus. Bydureon BCise, Trulicity, and Victoza are indicated in patients 10 years of age and older, while the other GLP-1 receptor agonists are indicated in adults.

Ozempic, Rybelsus, Trulicity, and Victoza are also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and:

- Established cardiovascular disease (*Ozempic, Trulicity, Victoza*);
- Cardiovascular risk factors (*Trulicity only*);
- Who are at high risk for these events (*Rybelsus only*).

Ozempic is additionally indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

**Limitation(s) of use:**

- Xultophy and Soliqua are not for the treatment of diabetic ketoacidosis. They have not been studied in combination with prandial insulin. In addition, they are not recommended for use in combination with any other product containing a GLP-1 receptor agonist.
- Bydureon BCise is an extended-release formulation of exenatide. Do not coadminister with other exenatide containing products.
- Victoza and Xultophy contain liraglutide and should not be co-administered with other liraglutide-containing products.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that GLP-1 receptor agonists are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Type 2 Diabetes Mellitus (must meet all):**

1. Diagnosis of type 2 diabetes mellitus;
2. Age is one of the following (a or b):
  - a. Bydureon BCise, Trulicity, Victoza:  $\geq 10$  years;
  - b. All other GLP-1 receptor agonists:  $\geq 18$  years;
3. Member meets one of the following (a, b, c, d, or e):
  - a. Request is for Soliqua;
  - b. Member has metabolic dysfunction-associated steatotic liver disease (MASLD), and (i):
    - i. Member is overweight (body mass index [BMI] 25-29.9 kg/m<sup>2</sup>) or obese (BMI  $\geq 30$  kg/m<sup>2</sup>);
  - c. Member has metabolic dysfunction-associated steatohepatitis (MASH), and (i):
    - i. Failure of  $\geq 3$  consecutive month trial of pioglitazone, unless contraindicated or clinically significant adverse effects are experienced;
  - d. Member has established atherosclerotic cardiovascular disease (ASCVD), indicators of high ASCVD risk (*see Appendix D*), heart failure with preserved ejection fraction, or chronic kidney disease, and both of the following (i and ii):
    - i. Request is for an agent with proven cardiovascular or renal benefit (Ozempic, Rybelsus, Trulicity, Victoza);
    - ii. Failure of  $\geq 3$  consecutive months of a sodium-glucose co-transporter 2 (SGLT2) inhibitor or SGLT2 inhibitor-containing product (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
  - e. For members without established ASCVD, indicators of high ASCVD risk (*see Appendix D*), heart failure with preserved ejection fraction, chronic kidney disease, MASLD, or MASH: Failure of  $\geq 3$  consecutive month trial of two agents from any of the following classes, unless clinically significant adverse effects are experienced or all are contraindicated: biguanides, sulfonylureas (SU), thiazolidinediones (TZD), dipeptidyl peptidase-4 inhibitors (DPP-4), or SGLT2 inhibitor or SGLT2 inhibitor-containing product (*see Appendix B*);
4. Member meets one of the following (a, b, c, or d):
  - a. If request is for Trulicity: Failure of liraglutide (Victoza), unless contraindicated or clinically significant adverse effects are experienced;
  - b. If request is for Soliqua: Member was prescribed one of the following within the past 180 days (i or ii):
    - i. Basal insulin (*see Appendix B*);
    - ii. GLP-1 receptor agonist;

- c. If request is for brand Victoza: Member must use liraglutide (Victoza), unless contraindicated or clinically significant adverse effects are experienced;
- d. If request is for a non-preferred GLP-1 receptor agonist: Failure of both of the following preferred GLP-1 receptor agonists (i and ii), each used for  $\geq 3$  consecutive months unless clinically significant adverse effects are experienced, both are contraindicated, or member has chronic kidney disease and request is for Ozempic:
  - i. Liraglutide (Victoza);
  - ii. If member has failed liraglutide (Victoza), then failure of Trulicity;
5. Requested product is not prescribed concurrently with another GLP-1 receptor agonist or a DPP-4 inhibitor (*see Appendix B for examples*);
6. Dose does not exceed the FDA-approved maximum recommended dose (*see Section V*).

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Type 2 Diabetes Mellitus (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Requested product is not prescribed concurrently with another GLP-1 receptor agonist or a DPP-4 inhibitor (*see Appendix B for examples*);
4. If request is for a dose increase, new dose does not exceed the FDA-approved maximum recommended dose (*see Section V*).

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AACE: American Association of Clinical Endocrinologists  
 ACE: American College of Endocrinology  
 ADA: American Diabetes Association  
 ASCVD: atherosclerotic cardiovascular disease  
 BMI: body mass index  
 DPP-4: dipeptidyl peptidase-4  
 eGFR: estimated glomerular filtration rate  
 ER: extended-release  
 FDA: Food and Drug Administration

GIP: glucose-dependent insulintropic polypeptide  
 GLP-1: glucagon-like peptide-1  
 HbA1c: glycated hemoglobin  
 IR: immediate-release  
 MASH: metabolic dysfunction-associated steatohepatitis  
 MASLD: metabolic dysfunction-associated steatotic liver disease  
 SGLT2: sodium-glucose co-transporter 2  
 SU: sulfonylureas  
 TZD: thiazolidinediones

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
<b>Biguanide</b>		
metformin (Fortamet <sup>®</sup> , Glucophage <sup>®</sup> , Glucophage <sup>®</sup> XR, Glumetza <sup>®</sup> )	Regular-release (Glucophage): 500 mg PO BID or 850 mg PO QD; increase as needed in increments of 500 mg/week or 850 mg every 2 weeks	Regular-release: 2,550 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	Extended-release: <ul style="list-style-type: none"> <li>Fortamet, Glumetza: 1,000 mg PO QD; increase as needed in increments of 500 mg/week</li> <li>Glucophage XR: 500 mg PO QD; increase as needed in increments of 500 mg/week</li> </ul>	Extended-release: 2,000 mg/day
<b>SGLT2 Inhibitors</b>		
Brenzavvy <sup>™</sup> (bexagliflozin)	20 mg PO QD	20 mg/day
dapagliflozin (Farxiga <sup>®</sup> )	5 mg PO QD	10 mg/day
	To reduce the risk of hospitalization for heart failure, the recommended dose is 10 mg PO QD	
Glyxambi <sup>®</sup> (empagliflozin/linagliptin)	One 10/5 mg tablet PO QD	25/5 mg/day
Invokamet <sup>®</sup> (canagliflozin/metformin)	One 50/500 mg tablet PO BID	300/2,000 mg/day
Invokamet <sup>®</sup> XR (canagliflozin/metformin)	Two 50/500 mg tablets PO QD	300/2,000 mg/day
Invokana <sup>®</sup> (canagliflozin)	100 mg PO QD	300 mg/day
Jardiance <sup>®</sup> (empagliflozin)	10 mg PO QD	25 mg/day
Qtern <sup>®</sup> (dapagliflozin/saxagliptin)	One 5/5 mg tablet PO QD	10/5 mg/day
Segluromet <sup>™</sup> (ertugliflozin/metformin)	Individualized dose PO BID	15/2,000 mg/day
Steglatro <sup>™</sup> (ertugliflozin)	5 mg PO QD	15 mg/day
Steglujan <sup>™</sup> (ertugliflozin/sitagliptin)	One 5/100 mg tablet PO QD	15/100 mg/day
Synjardy <sup>®</sup> (empagliflozin/metformin)	Individualized dose PO BID	25/2,000 mg/day
Synjardy <sup>®</sup> XR (empagliflozin/metformin)	Individualized dose PO QD	25/2,000 mg/day
Trijardy <sup>™</sup> XR (empagliflozin/linagliptin/metformin)	Individualized dose PO QD	25/5/2,000 mg/day
Xigduo <sup>®</sup> XR (dapagliflozin/metformin)	Individualized dose PO QD	IR: 40mg/day XR: 20 mg/day
<b>SUs</b>		
glipizide	Instant-release, extended-release: 5 mg tablet PO QD	10 mg/day
glimepiride (Amaryl <sup>®</sup> )	1-2 mg tablet PO QD	8 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
glyburide, Micronized glyburide (Glynase <sup>®</sup> )	2.5- 5 mg tablet PO QD	20 mg/day
<b>TZDs</b>		
pioglitazone (Actos <sup>™</sup> )	15-30 mg tablet PO QD	45 mg/day
<b>DPP-4 Inhibitors</b>		
Jentadueto <sup>®</sup> (linagliptin/metformin)	Individualized dose PO BID	5/2,000 mg/day
Jentadueto <sup>®</sup> XR (linagliptin/metformin)	Individualized dose PO QD	5/2,000 mg/day
Kazano <sup>®</sup> (alogliptin/metformin)	Individualized dose PO BID	25/2,000 mg/day
Kombiglyze XR <sup>®</sup> (saxagliptin/metformin)	Individualized dose PO QD	5/2,000 mg/day
Nesina <sup>®</sup> (alogliptin)	25 mg tablet PO QD	25 mg/day
Onglyza <sup>®</sup> (saxagliptin)	2.5 or 5 mg tablet PO QD	5 mg/day
Oseni <sup>®</sup> (alogliptin/pioglitazone)	Individualized dose PO QD	25/45 mg/day
Tradjenta <sup>®</sup> (linagliptin)	5 mg tablet PO QD	5 mg/day
pioglitazone (Actos <sup>™</sup> )	15-30 mg tablet PO QD	45 mg/day
<b>Basal Insulins</b>		
Insulin determine (Levemir <sup>®</sup> )	Individualized dose SC QD or BID	Not applicable
Insulin glargine (Lantus <sup>®</sup> , Toujeo <sup>®</sup> , Basaglar <sup>®</sup> , Semglee <sup>®</sup> )	Individualized dose SC QD	Not applicable
Insulin degludec (Tresiba <sup>®</sup> )	Individualized dose SC QD	Not applicable

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

#### *Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s):
  - Hypersensitivity to any product components
  - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (*all GLP-1 receptor agonists other than Byetta and Soliqua*)
  - Use during episodes of hypoglycemia (*Xultophy and Soliqua only*)
  - History of drug-induced immune-mediated thrombocytopenia from exenatide products (*Bydureon BCise and Byetta only*)
- Boxed warning(s): thyroid C-cell tumors (*all GLP-1 receptor agonists other than Byetta and Soliqua*)

#### *Appendix D: General Information*

- Per the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) guidelines:



- Metformin is recommended for all patients with type 2 diabetes. It is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death. Monotherapy is recommended for most patients; however:
  - Starting with dual therapy (i.e., metformin plus another agent, such as a SU, TZD, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist, or basal insulin) may be considered for patients with baseline HbA1c  $\geq 1.5\%$  above their target. According to the ADA, a reasonable HbA1c target for many non-pregnant adults is  $< 7\%$  ( $\leq 6.5\%$  per the AACE/ACE).
  - Starting with combination therapy with insulin may be considered for patients with baseline HbA1c  $> 10\%$  or if symptoms of hyperglycemia are present.
  - For patients with established ASCVD or indicators of high ASCVD risk, heart failure, or chronic kidney disease, use of an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of HbA1c and metformin use. For heart failure, GLP-1 receptor agonists are specifically recommended for obese patients with preserved ejection fraction, while SGLT2 inhibitors are recommended regardless of ejection fraction or presence of obesity.
  - For patients with MASLD, GLP-1 receptor agonists are recommended for glycemic management due to potential beneficial effects on MASLD.
  - For patients with MASH, GLP-1 receptor agonists, pioglitazone, or a combination of the two are recommended for glycemic management due to potential beneficial effects on MASH.
- If the target HbA1c is not achieved after approximately 3 months of monotherapy, dual therapy should be initiated. If dual therapy is inadequate after 3 months, triple therapy should be initiated. Finally, if triple therapy fails to bring a patient to goal, combination therapy with insulin should be initiated. Each non-insulin agent added to initial therapy can lower HbA1c by 0.7-1%.
- Although Trulicity is currently the only GLP-1 receptor agonist that is FDA approved for use in patients with multiple cardiovascular risk factors, the ADA guidelines recognize Ozempic, Trulicity, and Victoza as agents that confer cardiovascular benefit and recommend the use of any of the three in patients at high risk of ASCVD, without preference for any one over the other. In addition, patients with multiple cardiovascular risk factors were included in each drug's cardiovascular outcomes trial.
- Examples of cardiovascular risk factors may include but are not limited to: dyslipidemia, hypertension, obesity, a family history of premature coronary disease, smoking, chronic kidney disease, and presence of albuminuria.
- According to the ADA, ASCVD includes coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin. Per American College of Cardiology, indicators of high ASCVD risk are age  $\geq 55$  years with coronary, carotid, or lower-extremity artery stenosis  $> 50\%$ ; left ventricular hypertrophy; retinopathy; and other end organ damage.
- Ozempic is the only GLP-1 receptor agonist with an FDA approved indication for use in diabetic patients with chronic kidney disease. Although Victoza and Trulicity have both shown benefit for renal end points in their cardiovascular outcomes trials in diabetic patients with established or high risk of cardiovascular disease, Ozempic is the only GLP-1 receptor agonist that has demonstrated benefit for progression of chronic kidney disease

in a chronic kidney disease-specific trial evaluating diabetic patients with chronic kidney disease. Of note, the ADA guidelines recommend use of GLP-1 receptor agonist with proven chronic kidney disease benefit in patients with chronic kidney disease.

**V. Dosage and Administration**

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Maximum Dose</b>
Bydureon BCise (exenatide ER)	2 mg SC once weekly	2 mg/week
Byetta (exenatide IR)	5 mcg to 10 mcg SC BID	20 mcg/day
Mounjaro (tirzepatide)	Initial dose: 2.5 mg SC once weekly. May increase by 2.5 mg every 4 weeks up to 15 mg once weekly	15 mg/week
Ozempic (semaglutide)	0.25 mg to 2 mg SC once weekly, increased no more frequently than every 4 weeks  For patients with type 2 diabetes and chronic kidney disease, the dosage should be increased to the maintenance dose of 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage	2 mg/week
Rybelsus (semaglutide)	Formulation R1:* Initial dose: 3 mg PO QD. After 30 days on the 3 mg dose, increase to 7 mg PO QD. May increase to 14 mg PO QD if needed for glycemic control after at least 30 days on the 7 mg dose  Formulation R2:* Initial dose: 1.5 mg PO QD. After 30 days on the 1.5 mg dose, increase to 4 mg PO QD. May increase to 9 mg PO QD if needed for glycemic control after at least 30 days on the 4 mg dose  <i>*Formulations R1 and R2 are not substitutable on a mg per mg basis. Use either formulation, but do not use both formulations at the same time. Patients may switch between formulations after 30 days of treatment (i.e., after the initiation phase). When switching between the formulations, initiate the other formulation the day after discontinuing the previous formulation.</i>	Formulation R1: 14 mg/day  Formulation R2: 9 mg/day
Soliqua (insulin glargine/lixisenatide)	Treatment naïve to basal insulin or GLP-1 receptor agonist, currently on a GLP-1 receptor agonist, or currently on	60 units insulin/ 20 mcg lixisenatide/day



Drug Name	Dosing Regimen	Maximum Dose
	less than 30 units of basal insulin daily: 15 units (15 units insulin/5 mcg lixisenatide) SC QD Currently on 30 to 60 units of basal insulin daily, with or without GLP-1 receptor agonist: 30 units (30 units insulin/10 mcg lixisenatide) SC QD	
Trulicity (dulaglutide)	0.75 mg to 1.5 mg SC once weekly For adults only: May increase to 3 mg once weekly if needed after at least 4 weeks on 1.5 mg dose. May further increase to 4.5 mg once weekly if needed after at least 4 weeks on 3 mg dose.	Pediatrics: 1.5 mg/week  Adults: 4.5 mg/week
Victoza (liraglutide)	Initial: 0.6 mg SC QD for 7 days Maintenance: 1.2 mg to 1.8 mg SC QD	1.8 mg/day
Xultophy (liraglutide/insulin degludec)	Treatment naïve to basal insulin or GLP-1 receptor agonist: 10 units (10 units of insulin/0.36 mg liraglutide) SC QD  Treatment experienced to basal insulin or GLP-1 receptor agonist: 16 units (16 units insulin/0.58 mg liraglutide) SC QD	50 units insulin/1.8 mg liraglutide/day

## VI. Product Availability

Drug Name	Availability
Bydureon BCise (exenatide ER)	Single-dose autoinjector: 2 mg
Byetta (exenatide IR)	Prefilled pen: 5 mcg/dose (0.02 mL) in 1.2 mL (60 doses), 10 mcg/dose (0.04 mL) in 2.4 mL (60 doses)
Mounjaro (tirzepatide)	<ul style="list-style-type: none"> <li>Single-dose prefilled pen: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL</li> <li>Single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL</li> </ul>
Ozempic (semaglutide)	Prefilled pen: <ul style="list-style-type: none"> <li>2 mg/3 mL (0.68 mg/mL); delivers 0.25 mg or 0.5 mg per injection</li> <li>4 mg/3 mL (1.34 mg/mL); delivers 1 mg per injection</li> <li>8 mg/3 mL (2.68 mg/mL); delivers 2 mg per injection</li> </ul>
Rybelsus (semaglutide)	<ul style="list-style-type: none"> <li>Tablets (formulation R1): 3 mg, 7 mg, 14 mg</li> <li>Tablets (formulation R2): 1.5 mg, 4 mg, 9 mg</li> </ul>

Drug Name	Availability
Soliqua (insulin glargine/lixisenatide)	Single-patient-use pen: 100 units/33mcg per mL in 3 mL
Trulicity (dulaglutide)	Single-dose prefilled pen: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL
Victoza (liraglutide)	Multi-dose prefilled pen: 18 mg/3 mL (6 mg/mL; delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg)
Xultophy (liraglutide/insulin degludec)	Single-patient use pen: 3.6 mg/100 units per mL in 3 mL

## VII. References

1. American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. December 2024; 48(suppl 1): S1-S352. Accessed November 17, 2025.
2. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: Developing a diabetes mellitus comprehensive care plan – 2022 update. Endocrine Practice. 2022; 28(10): 923-1049.
3. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023 May;29(5):305-340. doi: 10.1016/j.eprac.2023.02.001.
4. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; dci220027. Available at: <https://diabetesjournals.org/care/article/doi/10.2337/dci22-0027/147614/Diabetes-Management-in-Chronic-Kidney-Disease-A>. Accessed November 17, 2025.
5. Bydureon BCise Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; May 2025. Available at: <https://www.astrazeneca-us.com/medicines/astrazeneca-medications.html>. Accessed October 24, 2025.
6. Byetta Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; September 2025. Available at: <https://www.azpicentral.com/pi.html?product=byetta>. Accessed October 24, 2025.
7. Trulicity Prescribing Information. Indianapolis, IN: Eli Lilly and Company, Inc; June 2025. Available at: [www.trulicity.com](http://www.trulicity.com). Accessed October 24, 2025.
8. Victoza Prescribing Information. Princeton, NJ: Novo Nordisk Inc; October 2025. Available at: [www.victoza.com](http://www.victoza.com). Accessed October 24, 2025.
9. Xultophy Prescribing Information. Bagsvaerd, Denmark: Novo Nordisk A/S; October 2025. Available at: [www.xultophy.com](http://www.xultophy.com). Accessed October 24, 2025.
10. Ozempic Prescribing Information. Bagsvaerd, Denmark: Novo Nordisk A/S; October 2025. Available at: [www.ozempic.com](http://www.ozempic.com). Accessed October 24, 2025.
11. Rybelsus Prescribing Information. Bagsvaerd, Denmark: Novo Nordisk A/S; October 2025. Available at: [www.rybelsuspro.com](http://www.rybelsuspro.com). Accessed October 29, 2025.
12. Mounjaro Prescribing Information. Indianapolis, IN: Lilly USA, LLC; September 2025. Available at: <https://uspl.lilly.com/mounjaro/mounjaro.html#pi>. Accessed October 24, 2025.
13. Soliqua Prescribing Information. Bridgewater, NJ: Sanofi-aventis US LLC; July 2025. Available at: [www.soliqua.com](http://www.soliqua.com). Accessed October 24, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: per November SDC removed Soliqua from criteria and added reference to CP.PST.01 step therapy criteria for Soliqua requests; WCG.CP.PMN.183 to be retired; references reviewed and updated.	11.30.21	02.22
RT4: added new dosage strength (2 mg) form for Ozempic.	04.13.22	
RT4: added newly FDA approved drug, Mounjaro.	05.31.22	
Template changes applied to other diagnoses/indications and continued therapy section.	10.04.22	
1Q 2023 annual review: RT4: added new dosage strength (2 mg/3 mL pen) for Ozempic; RT4: added pediatric expansion for age $\geq 10$ years for Trulicity; references reviewed and updated. Per November SDC, updated redirections from requiring metformin + SGLT2 to requiring two agents from any of the following classes: biguanides, SU, TZD, DPP-4 inhibitors, SGLT2 inhibitors; added bypass of required trial agents for members with ASCVD, indicators of high ASCVD risk, or chronic kidney disease per ADA guidelines; for non-preferred GLP-1 agents added criteria to require preferred GLP-1 products (e.g., Bydureon, Bydureon BCise, Byetta, Trulicity, Adlyxin). RT4: removed limitation of use regarding first line use for Rybelsus per updated PI.	01.17.23	02.23
Per February SDC, added Soliqua requiring use of either basal insulin or GLP-1 receptor agonist within the past 180 days.	02.21.23	05.23
Added the following requirement to both initial and continued therapy: requested product is not prescribed concurrently with another GLP-1 receptor agonist.	07.31.23	
RT4: Added newly approved Mounjaro vial formulations.	09.12.23	
1Q 2024 annual review: no significant changes; for Ozempic, removed 2 mg/1.5 mL (1.34 mg/mL) from section VI as strength is not currently marketed; updated Appendix D; references reviewed and updated. Per December SDC, removed Adlyxin as an example of a preferred GLP-1 receptor agonist.	12.06.23	02.24
Per March SDC, added Victoza as a preferred agent for Ozempic in member established cardiovascular disease or multiple cardiovascular risk factors added Victoza as an additional required step; removed Bydureon from criteria as product has been discontinued.	03.12.24	05.24
Per SDC, modified step therapy requirement for non-preferred agents from one preferred agent to all preferred agents; added bypass of step therapy requirements for preferred agents.	07.01.24	
Per September SDC: removed redirection to Bydureon BCise and Byetta; removed redirection to brand Victoza and added redirection to liraglutide (Victoza authorized generic); revised redirection of preferred agents in a stepwise fashion, first requiring liraglutide (Victoza authorized generic), then if member has failed liraglutide,	09.25.24	12.24

Reviews, Revisions, and Approvals	Date	P&T Approval Date
member must fail Trulicity; removed redirection criterion for Ozempic in members with established cardiovascular disease or multiple cardiovascular risk factors as redirection through liraglutide and Trulicity now align with all non-preferred products; added disclaimer that manufacturer AstraZeneca has discontinued Bydureon BCise and Byetta products.		
1Q 2025 annual review: no significant changes; added Brenzavvy to Appendix B; references reviewed and updated. RT4: added new Rybelsus formulation (R2 tablets: 1.5 mg, 4 mg, and 9 mg); per 2025 ADA guidelines, added bypass of required non-GLP-1 trial agents for members with MASLD, MASH, and heart failure with preserved ejection fraction.	12.17.24	02.25
RT4: updated criteria to reflect Ozempic's new FDA indication for use in diabetic patients with chronic kidney disease; added "renal" benefit to criterion I.A.3.d.i. Per SDC, revised "liraglutide (Victoza authorized generic)" to "liraglutide (Victoza)".	02.12.25	
Clarified for Bydureon BCise age should be $\geq 10$ years.	05.27.25	
Added requirement for no concurrent use with DPP-4 inhibitors, consistent with the existing duplicate therapy edit for these agents. RT4: updated criteria to reflect Rybelsus's new FDA indication for reduction of major adverse cardiovascular events in diabetic patients at high risk.	10.29.25	12.25
1Q 2026 annual review: no significant changes; removed Adlyxin as it is no longer commercially available; references reviewed and updated.	11.17.25	02.26

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage

decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.